Binaytara Foundation’s 2023 Summit on Cancer Health Disparities: Call for Abstracts

Submit Your Research for Presentation at Our Cancer Disparities Summit

The Binaytara Foundation invites you to submit your research for our Summit on Cancer Health Disparities (SCHD23) in Seattle, WA, on April 28-30, 2023! The submission deadline is January 31, 2023.

SCHD23 is one of the largest gatherings of clinicians and researchers interested in cancer health disparities. Accepted abstracts will be published in the International Journal of Cancer Care & Delivery (IJCCD)Submit here!

Best Abstract Award

The three highest-scoring abstracts submitted by a fellow or resident will receive complimentary registration and two free hotel nights during the conference. A fellow or resident must be the first author of the abstract.

We will accept abstracts in the following categories:

Technology

Tumor biology

Precision oncology

Epidemiology

Screening

Health policy

Survivorship

Quality improvement

Database analysis

Encore abstracts: The abstract committee will accept encore clinical trials abstracts for this conference. Submissions with additional data that supplement the previous presentation will be preferred. Authors should provide information regarding the original presentation, including the name of the meeting where the abstract was originally presented.

Watch these videos to hear from Dr. Dan Milner of the American Society of Clinical Pathology, Dr. Evan Glazer of the University of Tennessee, and Dr. Binay Shah with the Binaytara Foundation on why you should submit an abstract!


The Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal. Donate here to change lives!

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

6 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

6 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

7 months ago